CapsoVision, Inc. AI Stock Analysis
Want to see CV full AI Analyst Report?
CapsoVision, Inc. (CV) AI Stock Analysis
CapsoVision, Inc.
(NASDAQ:CV)
The score is held back primarily by weak financial performance—very large operating losses and heavy cash burn—despite strong revenue growth and low current leverage. Technicals are also soft with the stock trading below key moving averages and negative MACD. These risks are partially offset by a constructive earnings call focused on meaningful regulatory/product milestones and guidance for improved revenue trajectory into 2H 2026 and 2027.
CapsoVision, Inc. (CV) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $365.62M
- Dividend Yield
- ―
- Average Volume (3M)
- 170.85K
- Price to Earnings (P/E)
- -11.2
- Beta (1Y)
- -1.15
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 99
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
CapsoVision, Inc. Business Overview & Revenue Model
Company Description
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of t...
CapsoVision, Inc. Earnings Call Summary
The call was predominantly positive, driven by FDA clearance and the U.S. launch of AI Highlights, completion of the CapsoCam Colon clinical study, new account growth, expanding patient utilization, financing resources and progress in the pancreatic cancer pipeline. The primary negatives were the competitive U.S. pricing environment, only 1% year-over-year revenue growth, lower gross profit and gross margin, and the company's continuing net loss. Overall, the milestones and strategic progress significantly outweighed the financial and commercial challenges.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
CapsoVision remains on track for submitting CapsoCam Colon before year-end 2026; the initial U.S. annual addressable market is approximately $1 billion, with the longer-term opportunity estimated to be over $10 billion. The company expects associated clinical expenses to decrease, providing an opportunity for a further operating expense decline, and believes revenue in the second half of 2026 will be higher than the first half; with AI Highlights launched on November 2, it expects sales of CapsoCam Plus to accelerate with the full impact realized in 2027. Site activation is advancing over dozen large volume centers, data will be available next month, and the company plans to commence the esophageal varices trial in the second half of next year.
CapsoVision, Inc. Financial Statement Overview
Summary
Revenue growth and solid gross margins are positives, and leverage is currently low. However, the financial profile is dominated by extremely large operating and net losses and significant, worsening cash burn, which elevates near-term funding and operating leverage risk.
Income Statement
26NegativeBalance Sheet
52NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 13.92M | 13.55M | 11.76M | 9.75M |
| Gross Profit | 6.92M | 7.17M | 6.38M | 5.49M |
| EBITDA | -28.86M | -24.95M | -19.40M | -10.96M |
| Net Income | -29.25M | -25.32M | -19.90M | -11.30M |
Balance Sheet | ||||
| Total Assets | 32.75M | 18.16M | 16.80M | 21.53M |
| Cash, Cash Equivalents and Short-Term Investments | 21.76M | 10.11M | 9.32M | 14.56M |
| Total Debt | 780.00K | 887.00K | 1.24M | 1.51M |
| Total Liabilities | 6.38M | 4.90M | 146.31M | 131.37M |
| Stockholders Equity | 26.37M | 13.26M | -129.51M | -109.84M |
Cash Flow | ||||
| Free Cash Flow | -29.27M | -22.95M | -20.24M | -11.56M |
| Operating Cash Flow | -29.20M | -22.86M | -20.09M | -10.80M |
| Investing Cash Flow | -78.00K | -90.00K | -153.00K | -754.00K |
| Financing Cash Flow | 33.28M | 23.60M | 15.07M | 20.53M |
CapsoVision, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CV, the sentiment is Positive. The current price of 6.82 is above the 20-day moving average (MA) of 6.62, above the 50-day MA of 6.55, and above the 200-day MA of 6.40, indicating a bullish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 56.13 is Neutral, neither overbought nor oversold. The STOCH value of 73.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CV.
CapsoVision, Inc. Risk Analysis
CapsoVision, Inc. disclosed 69 risk factors in its most recent earnings report. CapsoVision, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksCapsoVision, Inc. Peers Comparison
Overall Rating
BSX64Neutral
CNMD63Neutral
TNDM53Neutral
CV50Neutral
LUCD48Neutral
PAVM26Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 64Neutral | $63.26B | 18.41 | 13.87% | ― | 8.88% | 25.77% | |
| 63Neutral | $1.43B | 19.84 | 7.07% | ― | 1.93% | 16.93% | |
| 53Neutral | $1.19B | -23.72 | -35.61% | ― | 6.73% | 76.54% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $365.62M | -11.18 | -160.22% | ― | ― | ― | |
| 48Neutral | $82.58M | -1.02 | -610.65% | ― | 23.60% | 54.50% | |
| 26Underperform | $12.07M | -0.14 | -58.07% | ― | 410.34% | -185.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CV | CapsoVision, Inc. | 6.82 | 1.59 | 30.40% | |
| BSX | Boston Scientific | 43.64 | -53.24 | -54.95% | |
| CNMD | Conmed Corporation | 48.01 | 5.23 | 12.23% | |
| TNDM | Tandem Diabetes Care | 17.05 | -4.23 | -19.88% | |
| PAVM | Pavmed | 1.32 | -8.80 | -86.96% | |
| LUCD | Lucid Diagnostics Inc. | 0.41 | -0.65 | -61.60% |
CapsoVision, Inc. Corporate Events
CapsoVision Wins FDA Clearance for AI Endoscopy Tool
PositiveCapsoVision, Inc., a NASDAQ-listed medical technology company specializing in AI-enabled capsule endoscopy for gastrointestinal disease detection, has built its business around the CapsoCam Plus capsule, supported by its CapsoView review software and...
CapsoVision Announces $18 Million Direct Stock Offering
PositiveOn September 17, 2026, CapsoVision, Inc. entered into a securities purchase agreement for a registered direct offering of 3,163,444 shares of common stock at $5.69 per share, a roughly 5% discount to the prior Nasdaq closing price. The offer, conduct...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
